PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8242709

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
INDI MOLECULAR, INC.	03/02/2022

RECEIVING PARTY DATA

Name:	REGENERON PHARMACEUTICALS, INC.
Street Address:	777 OLD SAW MILL RIVER ROAD
City:	TARRYTOWN
State/Country:	NEW YORK
Postal Code:	10591

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	13601023
Application Number:	14149520
Application Number:	15211759
Application Number:	16827001
Application Number:	15478596
Application Number:	15072039
Application Number:	17322493
Application Number:	15420596
Application Number:	16879611
Application Number:	16673657
Application Number:	16817458

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 404-879-2150
Email: kathleen@pabstpatent.com, yvonne@pabstpatent.com, docketing@pabstpatent.com
Correspondent Name: PABST PATENT GROUP LLP
Address Line 1: 1355 PEACHTREE STREET NE, SUITE 800
Address Line 4: ATLANTA, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	REGN GENERAL
NAME OF SUBMITTER:	KATHLEEN SAURER
SIGNATURE:	/KATHLEEN SAURER/
DATE SIGNED:	10/26/2023

Total Attachments: 8
source=REGN Patent ASN Indi to Regeneron#page1.tif
source=REGN Patent ASN Indi to Regeneron#page2.tif
source=REGN Patent ASN Indi to Regeneron#page3.tif
source=REGN Patent ASN Indi to Regeneron#page4.tif
source=REGN Patent ASN Indi to Regeneron#page5.tif
source=REGN Patent ASN Indi to Regeneron#page6.tif
source=REGN Patent ASN Indi to Regeneron#page7.tif
source=REGN Patent ASN Indi to Regeneron#page8.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "***Assignment***"), made and entered into this 2nd day of March, 2022 ("***Effective Date***"), by and between Indi Molecular, Inc., a Delaware corporation ("***Assignor***") and Regeneron Pharmaceuticals, Inc., a New York corporation ("***Assignee***"). Assignor and Assignee may each be referred to herein individually as a "***Party***" and, collectively, as the "***Parties***." All capitalized terms used in this Assignment but not otherwise defined herein have the meaning ascribed to them in the APA (as defined below).

WHEREAS, concurrently with the execution and delivery of this Assignment, Assignor and Assignee are entering into that certain Asset Purchase Assignment (the "***APA***") pursuant to which Assignor has agreed to sell, transfer, assign, convey and deliver to Assignee, among other assets, the Patents (as defined below) and Assignor has agreed to execute and deliver this Assignment for recording with the United States Patent and Trademark Office and corresponding Governmental Authorities in other applicable jurisdictions.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignment. Assignor hereby irrevocably assigns to Assignee, and Assignee hereby accepts from Assignor, all of Assignor's right, title and interest in and to the patents and patent applications set forth on Exhibit A attached hereto and all issuances, reissues, divisions, continuations, continuations-in-part, extensions, reexaminations and renewals thereof (collectively, the "***Patents***"), including all (i) income, royalties and other proceeds now or hereafter due or payable with respect to such Patents and (ii) rights to bring actions, whether at law or in equity, and to recover damages, lost profits and secure injunctive and other legal and equitable relief for all past, present and future infringements, misappropriations and other violations of such Patents.

2. Recordation and Further Assurances. Assignor hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding Governmental Authorities in other applicable jurisdictions to record this Assignment upon Assignee's request. From and after the Effective Date, Assignor shall execute and deliver such additional documents and take such further actions as Assignee and its successors, assigns and its and their respective legal representatives may request, at their sole cost and expense, to effectuate, evidence or perfect the assignment of the Patents to Assignee or any successor or assignee thereto.

3. Terms of the APA. This Assignment is entered into pursuant to the APA, to which reference is made for a further statement of the rights and obligations of Assignor and Assignee with respect to the Patents. The representations, warranties, covenants, agreements and indemnities contained in the APA shall not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the APA and the terms hereof, the terms of the APA will govern.

4. Governing Law. This Assignment and all disputes and causes of action based upon, arising out of or relating to this Assignment will be governed by and construed in accordance with the laws of the United States and the State of Delaware, without giving effect to any choice of law provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the laws of the United States and the State of Delaware.

5. Counterparts. This Assignment may be signed in any number of counterparts, each of which will be deemed to be an original, with the same effect as if the signatures on each counterpart were upon the same instrument. Signatures may be delivered via electronic mail, facsimile or other form of electronic transmission.

6. Successors and Assigns. This Assignment will be binding on and inure to the benefit of the Parties and their respective successors and assigns.

[*Signature page follows*]

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

ASSIGNEE:

REGENERON PHARMACEUTICALS, INC.

By:_____
Name: Nouhad Husseini
Title: SVP, Head of Business Development and Corporate Strategy

[*Signature Page to Patent Assignment*]

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

ASSIGNOR:

INDI MOLECULAR, INC.

By: DocuSigned by: Al Luderer
6AB8D65ACA8B43F...

Name: Albert A. Luderer

Title: CEO

EXHIBIT A

PATENTS

Indi: 10.1 US
Title: Akt-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Steven W. Millward, James R. Heath, Arundhati Nag, Samir Das, Kaycie M. Deyle, Paul E. Kearney
Filed: 7/11/2012
App: 13/546,575
Reg. 9,239,332
Issue Date: 1/19/2016

Indi: 11.1 US
Title: VEGF-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Paul E. Kearney, Suresh Mark Pitram, Tsun Yin Lai, Rosemary D. Rohde, Heather D. Agnew
Filed: 8/31/2012
App.: 13/601,023
Reg.: 8,710,180
Issue Date: 4/29/2014

Indi: 11.1 C1
Title: VEGF-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Paul E. Kearney, Suresh Mark Pitram, Tsun Yin Lai, Rosemary D. Rohde, Heather D. Agnew, Scott Law, Kenneth Charles Fang
Filed: 1/7/2014
App.: 14/149,520
Reg.: 9,221,889
Issue Date: 12/29/2015

Indi: 27.1 US
Title: IL-17F-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
App.: 7/15/2016
App:. 15/211,759
Reg.: 10,598,671
Issue Date: 3/24/2020

Indi: 27.1 C1
Title: IL-17F-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 3/23/2020
App.: 16/827,001

Indi: 27.1 CN
Title: IL-17F-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 7/15/2016
App.: 201680053464.6

Indi: 27.1 EP
Title: IL-17F-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 7/15/2016
App.: 16745579.9

Indi: 27.1 IL
Title: IL-17F-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 7/15/2016
App.: 256833

Indi 29.1 US
Title: CD8-Specific Capture Agents, Compositions, and Methods of Using and MakingInventors: Heather D. Agnew, Bert Tsunyin Lai
Filed: 4/4/2017
App.: 15/478,596

Indi 29.1 CN
Title: CD8-Specific Capture Agents, Compositions, and Methods of Using and MakingInventors: Heather D. Agnew, Bert Tsunyin Lai
Filed: 4/4/2017
App.: 201780034783.7

Indi 29.1 EP
Title: CD8-Specific Capture Agents, Compositions, and Methods of Using and MakingInventors: Heather D. Agnew, Bert Tsunyin Lai
Filed: 4/4/2017
App.: 17722528.1
Reg.: 3440101
Issue Date: 10/6/2021

Validate: DE, NL

Indi: 30.1 US
Title: Botulinum Neurotoxin-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Heather D. Agnew , Blake Farrow, James R. Heath
Filed: 3/16/2016
App.: 15/072,039
Reg.: 9,913,875
Issued: 3/13/2018

Indi: 30.1 C1
Title: Botulinum Neurotoxin-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Heather D. Agnew , Blake Farrow, James R. Heath
Filed: 5/17/2021
App.: 17/322,493

Indi: 30.1 D1
Title: Botulinum Neurotoxin-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Heather D. Agnew , Blake Farrow, James R. Heath
Filed: 1/31/2017
App.: 15/420,596
Reg.: 11,007,245
Issue: 5/18/2021

Indi: 30.1 CN
Title: Botulinum Neurotoxin-Specific Capture Agents, Compositions, and Methods of Using and Making
Inventors: Heather D. Agnew , Blake Farrow, James R. Heath
Filed: 3/16/2016
App.: 201680016366.5

Indi 31.1 US
Title: Compositions For Detection, Inhibition and Imaging Of Indoleamine 2, 3-Dioxygenase 1 (IDO1) And Methods Of Making and Using Same
Inventors: Bert Tsunyin Lai, Heather D. Agnew
Filed: 9/29/2017
App.: 15/721,512

Indi 31.1 US
Title: Compositions For Detection, Inhibition and Imaging Of Indoleamine 2, 3-Dioxygenase 1 (IDO1) And Methods Of Making and Using Same
Inventors: Bert Tsunyin Lai, Heather D. Agnew
Filed: 9/29/2017

App.: 15/721,512

Indi: 31.1 C1
Title: Compositions and Methods Relating to Detection, Inhibition, and Imaging of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Inventors: Heather D. Agnew, Anders Eliasen, Bert Tsunyin Lai
Filed: 5/20/2020
App.: 16/879,611

Indi: 31.1 EP
Title: Compositions and Methods Relating to Detection, Inhibition, and Imaging of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Inventors: Heather D. Agnew, Anders Eliasen, Bert Tsunyin Lai
Filed: 9/29/2017
App.: 17794115.0

Indi: 32.1 US
Title: IL-17F And IL-17A-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 6/15/2018
App.: 16/010,347

Indi: 32.1 EP
Title: IL-17F And IL-17A-Specific Capture Agents, Compositions, And Methods Of Using And Making
Inventors: James R. Heath, Heather D. Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
Filed: 6/15/2018
App.: 18739996.9

Indi: 36.1 US
Title: Peptide Libraries With Non-Canonical Amino Acids
Inventor: Anders Eliasen
Filed.: 11/4/2019
App.: 16/673,657

- -

Indi: 37.2 US
Title: Cross-Linked Epitopes and Methods of Use Thereof
Inventors: Anders Eliasen, Bert Tsunyin Lai
Filed: 3/12/2020
App.: 16/817,458